{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:12:04Z","timestamp":1792159924909,"version":"4.4.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Drugs with anticholinergic properties are frequently prescribed to patients with cognitive impairment. The cholinergic system plays an important role in learning processes, memory, and emotions regulation. The aim of this research is to report use of anticholinergic drugs in a clinical population and to investigate the correlation between the use of anticholinergic drugs and the risk of presenting with more severe behavioral and psychological symptoms (BPSD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Patients with a diagnosis of subjective cognitive impairment, mild cognitive impairment (MCI) or dementia were recruited. Screening tests for cognitive impairment (MMSE) and functional status (ADL, IADL) were performed. BPSD were evaluated with the Neuropsychiatric Inventory (NPI). The anticholinergic burden was calculated using the ACB calculator. We compared patients at low risk of anticholinergic adverse effects (ACB\u202f&amp;lt;\u202f3) versus patients at high risk (ACB\u202f\u2265\u202f3). Chi-square test and Mann\u2013Whitney test were used to compare the two groups. A multiple linear regression was performed to identify factors associated with higher NPI score and a logistic regression model was built to identify drug classes associated with ACB\u202f\u2265\u202f3.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>A total of 173 patients (mean age 74\u202f\u00b1\u202f7, 74 men) were included in the study; 132 patients with ACB\u202f&amp;lt;\u202f3 (low risk) versus 41 patients with ACB \u22653 (high risk) were compared. No statistically significant differences were found between the two groups in terms of demographics (age, sex) and anamnestic variables (education, marital status, family history of dementia, hypertension, diabetes, smoking, dyslipidemia, atrial fibrillation, coronary heart disease and use of alcohol). Significantly higher NPI scores were found in patients with ACB\u202f\u2265\u202f3 (mean scores 47.3\u202f\u00b1\u202f34.8 versus 25.5\u202f\u00b1\u202f24.6, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001). Patients with ACB\u202f\u2265\u202f3 showed lower MMSE (18.5\u202f\u00b1\u202f8.6 versus 22.4\u202f\u00b1\u202f7, <jats:italic>p<\/jats:italic>\u202f=\u202f0.004) and more IADLs lost. In the multivariate regression analysis, after adjusting for age, sex, polypharmacy and IADLs lost, only the MMSE and the ACB scores were independent predictors of the NPI score. Being on antipsychotics, antidepressants and antidiabetic drugs was associated with increased risk of higher anticholinergic burden.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conclusion, the anticholinergic burden might play a significant role as a risk factor for developing more severe BPSD in patients with cognitive decline, independently from their degree of cognitive impairment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1505007","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:29:11Z","timestamp":1739345351000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Anticholinergic burden and behavioral and psychological symptoms in older patients with cognitive impairment"],"prefix":"10.3389","volume":"12","author":[{"given":"Sabrina","family":"Pistorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Scotto di Tella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Canzanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Merenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Cuomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Iacotucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Carnovale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Bencivenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalaura","family":"Manes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Cataldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Zanetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia Daniela","family":"Femminella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fneur.2012.00073","article-title":"Behavioral and psychological symptoms of dementia","volume":"3","author":"Cerejeira","year":"2012","journal-title":"Front Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1017\/S1041610218000534","article-title":"Management of behavioral and psychological symptoms in people with Alzheimer\u2019s disease: an international Delphi consensus","volume":"31","author":"Kales","year":"2019","journal-title":"Int Psychogeriatr"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.mad.2005.09.016","article-title":"Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer\u2019s disease","volume":"127","author":"Lanari","year":"2006","journal-title":"Mech Ageing Dev"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.arr.2011.01.003","article-title":"Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer\u2019s type","volume":"10","author":"Pinto","year":"2011","journal-title":"Ageing Res Rev"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ph14030246","article-title":"Behavioral and psychological symptoms in dementia (BPSD) and the use of antipsychotics","volume":"14","author":"Calsolaro","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1046\/j.1532-5415.2002.50208.x","article-title":"Use of anticholinergic medications by older adults with dementia","volume":"50","author":"Roe","year":"2002","journal-title":"JAGS"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/1745509X.4.3.311","article-title":"Impact of anticholinergics on the aging brain: a review and practical application","volume":"4","author":"Boustani","year":"2008","journal-title":"Aging Health"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00228-020-02994-x","article-title":"Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review","volume":"77","author":"Lisibach","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00228-015-1932-x","article-title":"Different methods, different results \u2013 how do available methods link a patient\u2019s anticholinergic load with adverse outcomes?","volume":"71","author":"Mayer","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12877-018-0929-6","article-title":"An anticholinergic burden score for German prescribers: score development","volume":"18","author":"Kiesel","year":"2018","journal-title":"BMC Geriatr"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"CD015196","DOI":"10.1002\/14651858.CD015196.pub2","article-title":"Anticholinergic burden for prediction of cognitive decline or neuropsyghiatric symptoms in older adults with mild cognitive impariment and dementia (review)","volume":"8","author":"Taylor-Rowan","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","article-title":"A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease","volume":"10","author":"Jessen","year":"2014","journal-title":"Alzheimers Dement"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/13607863.2014.920303","article-title":"The new DSM-5 diagnosis of mild neurocognitive disorder and its relation to research in mild cognitive impairment","volume":"19","author":"Sachs-Ericsson","year":"2015","journal-title":"Aging Ment Health"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/gps.1610","article-title":"The Addenbrooke\u2019s cognitive examination revised (ACE-R): a brief cognitive test battery for dementia screening","volume":"21","author":"Mioshi","year":"2006","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref15","first-page":"S10","volume-title":"The neuropsychiatric inventory: assessing psychopatology in dementia patients neurology","year":"1997"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s12603-016-0787-x","article-title":"Anticholinergic burden and functional status in older people with cognitive impairment: results from the regal project","volume":"21","author":"Boccardi","year":"2017","journal-title":"J Nutr Health Aging"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","article-title":"Studies of illness in the aged. The index of ADL: a standardized measure of biologicaland psychosocial function","volume":"185","author":"Katz","year":"1963","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaning and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"The Gerontologist"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/sj.clpt.6100435","article-title":"Drugs with anticholinergic properties as a risk factor for psychosis in patients affected by Alzheimer\u2019s disease","volume":"84","author":"Cancelli","year":"2008","journal-title":"Clin Pharmacol Therapeut"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1389014","DOI":"10.3389\/fendo.2024.1389014","article-title":"Impact of serum leptin and adiponectin levels on brain infarcts in patients with mild cognitive impairment and Alzheimer\u2019s disease: a longitudinal analysis","volume":"15","author":"Carbone","year":"2024","journal-title":"Front Endocrinol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10888-011-9214-z","article-title":"Decomposition procedures for distributional analysis: a unified framework based on the Shapley value","volume":"11","author":"Shorrocks","year":"2013","journal-title":"J Econ Inequal"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/sj.clpt.6100035","article-title":"Anticholinergic drugs and physical function among frail elderly population","volume":"81","author":"Landi","year":"2007","journal-title":"Clin Pharmacol Therapeut"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e044230","DOI":"10.1136\/bmjopen-2020-044230","article-title":"Anticholinergic drug burden according to the anticholinergic drug scale and the German anticholinergic burden and their impact on cognitive function in multimorbid elderly German people: a multicentre observational study","volume":"11","author":"Kr\u00fcger","year":"2021","journal-title":"Br Med J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13195-017-0284-4","article-title":"Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders","volume":"9","author":"Dauphinot","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3233\/JAD-170265","article-title":"Potentially inappropriate medication, anticholinergic burden, and mortality in people attending memory clinics","volume":"60","author":"Cross","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.tips.2022.09.006","article-title":"Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic","volume":"43","author":"Yohn","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/S2215-0366(24)00100-7","article-title":"Psychosis as a disorder of muscarinic signalling: psychopathology and pharmacology","volume":"11","author":"McCutcheon","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch Neurol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"6921","DOI":"10.3390\/ijms24086921","article-title":"Cholinergic antagonists and behavioral disturbances in neurodegenerative diseases","volume":"24","author":"Mahmoudi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"CD013540","DOI":"10.1002\/14651858.CD013540.pub2","article-title":"Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome (review)","volume":"5","author":"Taylor-Rowan","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/bcpt.12699","article-title":"A novel scale linking potency and dosage to estimate anticholinergic exposure in older adults: the muscarinic Acetylcholinergic receptor ANTagonist exposure scale","volume":"120","author":"Klamer","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1186\/s12877-023-04225-1","article-title":"Development of the Swedish anticholinergic burden scale (Swe-ABS)","volume":"23","author":"Rube","year":"2023","journal-title":"BMC Geriatr"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1505007\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:29:13Z","timestamp":1739345353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1505007\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":33,"alternative-id":["10.3389\/fmed.2025.1505007"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1505007","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"article-number":"1505007"}}